Phase I-II clinical trial of californium-252. Treatment of stage IB carcinoma of the cervix
โ Scribed by Yosh Maruyama; John R. Vannagell; Justine Yoneda; Elvis Donaldson; Holly Gallion; Ken Rowley; Richard Kryscio; Joseph L. Beach
- Publisher
- John Wiley and Sons
- Year
- 1987
- Tongue
- English
- Weight
- 656 KB
- Volume
- 59
- Category
- Article
- ISSN
- 0008-543X
No coin nor oath required. For personal study only.
๐ SIMILAR VOLUMES
## Background: Patients with metastatic carcinoma of the uterine cervix have limited survival. thus, new chemotherapeutic agents and combinations are needed to improve patient outcome. ## Methods: Twenty-seven patients with stage iv primary or recurrent carcinoma of the uterine cervix were assign
Local failure (in the cervix and pelvic wall) continues to be a major reason for poor results following conventional radiation treatment of Stage IIIB (FIGO) carcinoma of the cervix. Attempting to minimize this local failure, in 1975 and early 1976, the Radiation Therapy Department, University of Ma
The clinical efficacy of LC9018, a biological response modifier prepared from heat-killed Lactobacillus casei YIT9018, used in combination with radiation was studied in a randomized controlled trial on 61 patients with carcinoma of the uterine cervix of Stage IIB or 111. The combination therapy with